These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations? Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687 [No Abstract] [Full Text] [Related]
6. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Kintscher U Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715 [No Abstract] [Full Text] [Related]
7. Effect of rimonabant on weight reduction and cardiovascular risk. Esposito K; Giugliano D Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931 [No Abstract] [Full Text] [Related]
8. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063 [No Abstract] [Full Text] [Related]
9. Effect of rimonabant on weight reduction and cardiovascular risk. Astrup A Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932 [No Abstract] [Full Text] [Related]
10. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
11. [Rimonabant. Risk of depression has not been finally clarified]. Kreutzkamp B Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079 [No Abstract] [Full Text] [Related]
12. [Endocannabinoid and endocannabinoid receptor antagonists]. Heinzl S Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333 [No Abstract] [Full Text] [Related]
13. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo. Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422 [No Abstract] [Full Text] [Related]
14. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Boekholdt SM; Jukema JW; Peters RJ Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262 [TBL] [Abstract][Full Text] [Related]
16. [The endocannabinoid system and treatment of obesity]. Aronsen L Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201 [TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Gadde KM; Allison DB Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206 [No Abstract] [Full Text] [Related]
18. [Prescription of rimonabant in the early stage of pregnancy?]. Picksak G; Stichtenoth DO Med Monatsschr Pharm; 2008 Mar; 31(3):107-8. PubMed ID: 18429532 [TBL] [Abstract][Full Text] [Related]
19. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S; Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887 [TBL] [Abstract][Full Text] [Related]
20. Rimonabant in obese patients with type 2 diabetes. Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094 [No Abstract] [Full Text] [Related] [Next] [New Search]